The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses

AIM: To evaluate the potential effects of therapeutic and supratherapeutic doses of linagliptin (BI 1356) on the QT/QT(c) interval in healthy subjects. METHODS: The study was a randomized, double-blind, placebo-controlled, four-period crossover study using single oral doses of linagliptin (5 mg and...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Ring, Arne, Port, Andreas, Graefe-Mody, E Ulrike, Revollo, Ivette, Iovino, Mario, Dugi, Klaus A
Format: Artigo
Idioma:Inglês
Publicat: Blackwell Science Inc 2011
Matèries:
Pharmacodynamics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3141185/
https://ncbi.nlm.nih.gov/pubmed/21306414
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2011.03931.x
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars